Tarbox Family Office Inc. Sells 2,445 Shares of Johnson & Johnson $JNJ

Tarbox Family Office Inc. cut its holdings in Johnson & Johnson (NYSE:JNJ) by 23.5% in the 4th quarter, HoldingsChannel.com reports. The fund owned 7,974 shares of the company’s stock after selling 2,445 shares during the period. Johnson & Johnson comprises about 0.3% of Tarbox Family Office Inc.’s holdings, making the stock its 29th biggest position. Tarbox Family Office Inc.’s holdings in Johnson & Johnson were worth $1,650,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently modified their holdings of the business. Abich Financial Wealth Management LLC bought a new position in Johnson & Johnson during the third quarter valued at about $26,000. Evolution Wealth Management Inc. bought a new position in Johnson & Johnson during the second quarter valued at about $27,000. Clayton Financial Group LLC bought a new position in Johnson & Johnson during the third quarter valued at about $28,000. Semmax Financial Advisors Inc. grew its position in Johnson & Johnson by 55.0% during the second quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock valued at $31,000 after buying an additional 72 shares during the period. Finally, Turning Point Benefit Group Inc. bought a new position in Johnson & Johnson during the third quarter valued at $41,000. 69.55% of the stock is owned by institutional investors.

Johnson & Johnson Price Performance

JNJ stock opened at $241.01 on Thursday. The firm has a 50 day moving average of $240.79 and a 200-day moving average of $214.35. The company has a current ratio of 1.03, a quick ratio of 0.77 and a debt-to-equity ratio of 0.48. Johnson & Johnson has a 12 month low of $141.50 and a 12 month high of $251.71. The firm has a market capitalization of $580.51 billion, a P/E ratio of 21.81, a price-to-earnings-growth ratio of 2.41 and a beta of 0.34.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Saturday, January 31st. The company reported $2.46 earnings per share (EPS) for the quarter. The company had revenue of $24.28 billion during the quarter. Johnson & Johnson had a return on equity of 33.04% and a net margin of 28.46%. As a group, sell-side analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson News Roundup

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Big analyst bullishness — Citigroup raised its price target to $285 and maintained a Buy, signaling a material upside to consensus; Guggenheim and TD Cowen also have Buy calls and lifted targets, supporting near-term demand. Citigroup raises price target to $285
• Positive Sentiment: New/maintained buy coverage from TD Cowen and supportive analyst commentary highlight J&J’s diversified pipeline and attractive risk/reward into earnings. TD Cowen / TipRanks coverage
• Positive Sentiment: Regulatory / product catalyst — J&J launched its next‑gen Varipulse Pro PFA catheter in Europe (CE mark), which could support device revenue growth in electrophysiology. Varipulse Pro launch in Europe
• Positive Sentiment: Specialty therapy wins — permanent U.S. reimbursement code for bladder cancer therapy INLEXZO and distribution deals (e.g., SIRTURO in Japan) reduce commercialization risk and boost revenue visibility in niche franchises. Johnson & Johnson updates key specialty therapies
• Neutral Sentiment: Media/analyst pieces are bullish ahead of Q1 — Barron’s and other outlets recommend buying into the earnings run-up, which supports momentum but also raises expectations risk. Barron’s: Buy ahead of earnings
• Neutral Sentiment: Mixed market commentary — coverage noting the stock “increases yet falls behind the market” and inclusion on low‑volatility/blue‑chip lists boost interest but are not direct fundamental drivers. Zacks: Increases yet falls behind market

Insider Buying and Selling at Johnson & Johnson

In related news, EVP Timothy Schmid sold 1,322 shares of Johnson & Johnson stock in a transaction on Friday, February 20th. The stock was sold at an average price of $245.66, for a total transaction of $324,762.52. Following the completion of the sale, the executive vice president owned 25,447 shares of the company’s stock, valued at approximately $6,251,310.02. This trade represents a 4.94% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Vanessa Broadhurst sold 6,197 shares of Johnson & Johnson stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $243.39, for a total transaction of $1,508,287.83. Following the sale, the executive vice president owned 23,003 shares of the company’s stock, valued at approximately $5,598,700.17. The trade was a 21.22% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 30,142 shares of company stock valued at $7,360,528 in the last three months. 0.16% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several equities analysts have weighed in on the company. Loop Capital set a $220.00 price objective on Johnson & Johnson in a report on Tuesday, January 27th. Wells Fargo & Company increased their price objective on Johnson & Johnson from $230.00 to $240.00 and gave the company an “overweight” rating in a report on Thursday, January 22nd. Barclays increased their price objective on Johnson & Johnson from $217.00 to $234.00 and gave the company an “equal weight” rating in a report on Thursday, March 19th. Daiwa Securities Group increased their target price on shares of Johnson & Johnson from $203.00 to $237.00 and gave the stock an “outperform” rating in a research report on Thursday, January 29th. Finally, HSBC increased their target price on shares of Johnson & Johnson from $265.00 to $280.00 and gave the stock a “buy” rating in a research report on Tuesday, March 17th. One analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $237.57.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.